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Abstract
Despite the clear public health benefit of insecticide-treated bednets (ITNs), the impact of malaria transmission-reduction by
vector control on the spread of drug resistance is not well understood. In the present study, the effect of sustained
transmission reduction by ITNs on the prevalence of Plasmodium falciparum gene mutations associated with resistance to
the antimalarial drugs sulfadoxine-pyrimethamine (SP) and chloroquine (CQ) in children under the age of five years was
investigated during an ITN trial in Asembo area, western Kenya. During the ITN trial, the national first line antimalarial
treatment changed from CQ to SP. Smear-positive samples collected from cross sectional surveys prior to ITN introduction
(baseline, n = 250) and five years post-ITN intervention (year 5 survey, n = 242) were genotyped for single nucleotide
polymorphisms (SNPs) at dhfr-51, 59, 108, 164 and dhps-437, 540 (SP resistance), and pfcrt-76 and pfmdr1-86 (CQ resistance).
The association between the drug resistance mutations and epidemiological variables was evaluated. There were significant
increases in the prevalence of SP dhps mutations and the dhfr/dhps quintuple mutant, and a significant reduction in the
proportion of mixed infections detected at dhfr-51, 59 and dhps-437, 540 SNPs from baseline to the year 5 survey. There was
no change in the high prevalence of pfcrt-76 and pfmdr1-86 mutations. Multivariable regression analysis further showed
that current antifolate use and year of survey were significantly associated with more SP drug resistance mutations. These
results suggest that increased antifolate drug use due to drug policy change likely led to the high prevalence of SP
mutations 5 years post-ITN intervention and reduced transmission had no apparent effect on the existing high prevalence
of CQ mutations. There is no evidence from the current study that sustained transmission reduction by ITNs reduces the
prevalence of genes associated with malaria drug resistance.
Citation: Shah M, Kariuki S, Vanden Eng J, Blackstock AJ, Garner K, et al. (2011) Effect of Transmission Reduction by Insecticide-Treated Bednets (ITNs) on
Antimalarial Drug Resistance in Western Kenya. PLoS ONE 6(11): e26746. doi:10.1371/journal.pone.0026746
Editor: Georges Snounou, Universite´ Pierre et Marie Curie, France
Received August 10, 2011; Accepted October 2, 2011; Published November 11, 2011
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: The study was supported by the Multilateral Initiative on Malaria grant # A40046 through the WHO Special Program for Research and Training in
Tropical Diseases and was partially supported by U.S. National Science Foundation, Ecology of Infectious Diseases grant # EF-0723770. Monica Shah was partially
supported by the Emerging Infectious Diseases Fellowship administered by the Association of Public Health Laboratories. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: yps0@cdc.gov
Introduction
Worldwide, three billion people are at risk of malaria infection.
Over 85% of the approximately 250 million cases and one million
deaths due to malaria occur in Africa each year [1]. Over the past
decade, the international community has emphasized the use of
malaria prevention to reduce the global burden of malaria as well as
to preserve the efficacy of the limited set of antimalarial treatment
drugs that are threatened by the emergence and spread of drug
resistance [2,3]. Current World Health Organization (WHO)-
recommended malaria control strategies include prompt access to
effective treatment, vector control with long lasting insecticide-
treated bednets (LLITNs) and indoor residual spraying (IRS), and
prevention of malaria in pregnancy [1]. ITNs, in particular, are
powerful and cost-effective malaria control tools [4,5]. In sub-
Saharan Africa, the use of ITNs has been associated with a 70–90%
decrease in malaria transmission, reduction in childhood malaria
morbidity and all-cause mortality, and significant decrease in
adverse effects of malaria in pregnancy [6,7,8].
Despite the clear benefit of ITNs on the prevention and control of
malaria, the impact of transmission reduction by ITN use on the
prevalence of antimalarial drug resistance genes in the areas where
parasite resistance has emerged due to drug pressure is not well-
known. To date, only a limited number of studies have examined
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the effect of vector control interventions on the spread of
antimalarial drug resistance and these studies have yielded
conflicting results. A study conducted in Tanzania found that
short-term use of ITNs was associated with decreased prevalence of
the dihydrofolate reductase (dhfr) triple mutant, which is associated
with resistance to the antimalarial drug sulfadoxine-pyrimethamine
(SP) [9]. After an IRS campaign conducted in Zimbabwe,
participants in sprayed villages had a lower risk of chloroquine
(CQ) treatment failure and lower prevalence of gene mutations in
the parasites conferring resistance to CQ compared to unsprayed
villages [10]. However, a study examining the effect of long-term
use of insecticide-treated curtains (ITCs) on antimalarial drug
resistance in Burkina Faso revealed no changes in the risk of CQ
treatment failure and prevalence of gene mutations linked to CQ
and SP in intervention compared to control villages [11].
Collectively, these results suggest that decreased transmission by
vector control may reduce the number of people exposed to drug
resistant parasites and the use of antimalarial treatment, and thus
lower drug pressure [9,10,11]. However, parasite and human host
factors , the genetic basis for drug resistance, and local human
migration might also affect the relationship between transmission
intensity and drug resistance [12].
Recent theoretical models [3,13] based on several field studies
describe the role of transmission intensity on the spread of drug
resistance as indirect. The intensity of transmission affects three
main epidemiological mediators: multiplicity of parasite clones,
infection risk, and acquired immunity. These three mediators
could respectively modulate the degree of sexual recombination of
parasites and the intrahost competition between co-infecting
parasite clones (intrahost dynamics), the level of drug use in the
population, the proportion of malaria infections treated, and the
number of parasites in a human host [3,12,13]. Additionally, the
relationship between transmission intensity and the spread of drug
resistance depends on whether resistance to a drug is encoded by a
single gene or by multiple genes. Some field evidence and
theoretical models have suggested that in the presence of intrahost
dynamics the rate of drug resistance, if the genetic basis of
resistance is monogenic, increases linearly from low to high
transmission intensity. However, drug resistance encoded by two
or more genes evolves faster in areas at the extremes of
transmission intensity, low and high, compared to intermediate
transmission [3,13,14].
At the molecular level, drug resistance develops through a series
of sequential mutations in genes that synergistically confer
resistance. Point mutations in Plasmodium falciparum dhfr and
dihydropteroate synthase (dhps) genes correlate with resistance to
pyrimethamine and sulfadoxine, respectively, while mutations in
chloroquine related transporter (pfcrt) and multidrug resistance
(pfmdr1) genes are linked with resistance to CQ [15]. In Africa, the
dhfr triple mutant, Asn-108/Ile-51/Arg-59, has been strongly
associated with clinical resistance to SP and the addition of the dhps
double mutant, Gly-437/Glu-540, creates the quintuple mutant
that is associated with in vivo SP treatment failure [16]. Mutations
at Tyr-86 in pfmdr1 and at Thr-76 in pfcrt genes are associated with
CQ resistance [17].
A better understanding of the relationship between the intensity
of transmission and the spread of genes that confer resistance to
antimalarial drugs could have significant public health implica-
tions, as the impact of transmission-reducing interventions may
award additional benefits if reduced transmission decreases the
spread of drug resistance. However, the relationship between
transmission intensity and drug resistance is complex and depends
on a number of factors; some can be measured directly while
others can only be estimated through proxies [12]. In the present
study, the impact of sustained transmission reduction by ITNs and
first line drug policy change from CQ to SP on the prevalence of
P. falciparum gene mutations associated with drug resistance to SP
and CQ was investigated during a large bednet trial conducted in
children under the age of five between 1996 and 2001 in western
Kenya. Using genetic, clinical, and epidemiological data, this
study (1) determined the prevalence of gene mutations associated
with SP and CQ drug resistance before and five years after ITN
intervention and (2) examined the association between epidemi-
ological variables and mutations in the SP and CQ-linked drug
resistance genes.
Materials and Methods
Study Site and Population
This study was part of a two-phase ITN trial carried out by the
Kenya Medical Research Institute (KEMRI) and US Centers for
Disease Control and Prevention (CDC) between 1996 and 2001 in
Asembo area, western Kenya, where malaria is holoendemic.
Detailed methods for the ITN trial are described elsewhere
[18,19]. During the trial, biannual population censuses and annual
cross-sectional surveys were conducted in 60 villages between
March and May (rainy season) to determine the impact of ITNs on
malaria-related morbidity and all-cause mortality in children
under the age of five. At each cross-sectional survey, blood samples
were collected, and parasitological, clinical, demographic, and
entomological information were recorded. P. falciparum accounted
for approximately 98% of malaria infections in the trial area [18].
For this study, 259 P. falciparum smear-positive blood samples
collected just prior to ITN introduction as baseline (year 1996 in
which the original survey only enrolled children under the age of
three years) [20] and 244 samples collected five years post-
intervention as ‘year 5 survey’ (year 2001 in which the original
survey recruited children under the age of five years) [18] were
randomly selected from the same subset of villages. The
entomologic inoculation rate (EIR) was recorded at 61.3 and 1.3
bites per person per year at baseline and five years after ITN
introduction, respectively [18,21]. Parasite prevalence in children
under the age of five decreased from 70% prior to the trial to 34%
at the year 5 survey [18,22]. ITN usage in children younger than
five years of age increased from ,5% at baseline to 82.5% at the
year 5 survey [18]. Overall, the number of people seeking
antimalarial treatment after ITN introduction decreased [22,23].
During the ITN trial, the national first line treatment for
uncomplicated malaria in children changed from CQ to SP in
1998. Prior to the policy change and implementation of ITNs
(year 1996), SP was sporadically available in health facilities and
prescribed occasionally (,1%) in the study area [23]. In addition,
cotrimoxazole (CTX, trimethoprim-sulfamethoxazole), a common
antifolate antimicrobial, acts as an antimalarial by inhibiting the
same enzymes in the folic acid biosynthetic pathway as SP. The
change from penicillin to CTX for first line treatment of
respiratory illnesses occurred in the mid-late 1990s in Kenya.
This study was approved by the Ethical Review Committee of
the KEMRI, Nairobi, Kenya, the Institutional Review Boards of
Michigan State University, East Lansing, MI, and the Centers for
Disease Control (CDC) Atlanta, Georgia. Written informed
consent was obtained from legal guardians of each child that
participated in this study.
Laboratory Procedures
DNA extraction. DNA was purified from red blood cell
pellets using the QIAamp DNA Blood Mini Kit (Qiagen, CA,
USA).
ITNs and Drug Resistance to SP and CQ
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SNP genotyping of drug resistance markers. Real-time
polymerase chain reaction (PCR) (Stratagene Mx3005P, CA,
USA) was used to detect single nucleotide polymorphisms (SNPs)
at dhfr-51, 59, 108 and 164, dhps-437 and 540, pfcrt-76 and pfmdr1-
86 using published procedures [24,25,26]. Briefly, standards and
field samples were run in duplicate in 25 mL reactions containing
TaqMan Universal Mastermix (Applied Biosystems, CA, USA),
2 mL of DNA (diluted 1:10), gene-specific forward and reverse
primers, and SNP-specific TaqMan MGB probes (Applied
Biosystems, CA, USA). Four ten-fold serial dilutions of both wild
type and mutant parasite laboratory strain standards, depending
on the SNP, and negative control templates were run on every
plate as positive and negative controls.
Definitions
Genetic definitions. For all eight SNPs genotyped, samples
were classified as (1) pure or mixed and (2) wild type or mutant. A
mixed sample contained PCR amplification of both wild type and
mutant strains with the minor strain .30% of the major strain
[27]. SP genotypes (dhfr, dhps, and combined dhfr/dhps) were
determined according to the criteria outlined by Kublin and
colleagues [16]. Briefly, dhfr genotype, based on mutations in dhfr-
51, 59, and 108, was classified as wild type, single, double, and
triple (pooled triple mixed and pure), dhps genotype (mutations in
dhps-437 and 540) as wild type, single, and double (pooled double
mixed and pure), and combined dhfr/dhps genotype (mutations in
dhfr-51,59,108 + dhps-437,540) as wild type, single, double, triple,
quadruple, quintuple (pooled quintuple mixed and pure). For
SNPs linked to CQ resistance, pfmdr1-86 and pfcrt-76 were
analyzed separately and genotypes were defined as wild type or
mutant. Furthermore, CQ and SP gene combined haplotypes
were defined based on SNP results for samples that were single
infection by RT-PCR at pfcrt-76, pfmdr1-86, dhfr-51, 59,108, and
dhps-437,540 [28,29].
As a previous study from our group using a subset of samples
showed that there was no change in multiplicity of infection (MOI)
measured by neutral microsatellites (MS) between baseline and the
year 5 survey [30], MOI data using the neutral MS markers were
not collected for the current study. Therefore, we estimated the
prevalence of mutations [16], which reflects the proportion of
human blood samples containing the mutation, rather than the
frequency of mutations, which measures the proportion of malaria
clones carrying a mutation [27]. Mixed infections for all SNPs
were considered mutant infections when calculating the preva-
lence of SNP mutations. The proportion of mixed infections was
defined as the number of mixed infections divided by the total
number of mutations (pure and mixed) in each SNP.
Clinical definitions. Epidemiological variables that were of
interest in the analysis included age, sex, parasite density,
hemoglobin level (g/dL), presence of gametocytes, report of
fever in previous 48 hours, geographic information system (GIS)
distance (in meters) to the Lake Victoria shore, nearest clinic,
nearest compound and elevation, and SP, CQ, and CTX drug use
within two weeks prior to surveys. As CTX has anti-malarial
properties through the same mechanism as SP, we also combined
the usage of SP and CTX as a single variable which we refer to as
antifolate to assess the relationship between antifolate drug
pressure and SP gene mutations.
Data Analysis
Differences between participant characteristics at baseline and
five years post-intervention were analyzed using chi-square and
two-sample t-tests (Satterthwaite’s statistic). Parasite density and
Euclidean distance to nearest compound were log transformed
prior to statistical testing. Differences in the prevalence of SNP
mutations, proportion of mixed infections in total mutations, and
prevalence of SP genotypes between baseline and post-interven-
tion samples were examined using chi-square tests. No adjustments
for multiple comparisons were made, as tests for each molecular
marker were considered independent.
To explore the association between epidemiological variables
and drug resistance genotype, univariable and multivariable
binary or cumulative logistic regression were used. As the
mutations in dhfr and dhps that confer resistance to SP occur
stepwise and sequentially and many studies have shown that
higher levels of resistance to SP occur when more mutations are
introduced, the outcome was modeled as an ordinal response
variable using cumulative logistic regression when other model
assumptions were met. Dhfr genotype was analyzed using logistic
regression by collapsing into two categories in order to ensure
sufficient sample size in each category for analysis: (1) wild type,
single, and double collapsed, and (2) triple mutations. Dhps
genotype was analyzed as three categories in the cumulative
logistic model: (1) wild type, (2) single, and (3) double mutations.
Dhfr and dhps combined genotype was classified into three
categories to ensure adequate sample size in each group and
analyzed using the cumulative logistic regression: (1) wild type,
single, double, and triple collapsed, (2) quadruple, and (3)
quintuple mutations. Two different multivariable models were
used, one with antifolate use (SP and/or CTX) and another with
only SP use as explanatory variables for drug use, due to expected
multicollinearity if both variables were added to the same model.
For each cumulative logistic model, the proportional odds
assumption was evaluated using the score test, where p,0.05
reflected a violation of the assumption. Logistic regression was
performed to assess the association between epidemiological
variables and mutations in pfcrt-76 or pfmdr1-86, considering wild
type as the reference category.
For both binary and cumulative logistic regression methods, the
final most parsimonious multivariable model was selected based on
biological plausibility, univariable analysis, and backwards elim-
ination strategy (removal cutoff p.0.10) after assessing interaction
and confounding. All possible two-way interaction terms with
primary exposures of interest (drug use and survey year) and
explanatory variables were examined using an overall likelihood
ratio test. The likelihood ratio test was insignificant for interaction
terms in all models using the a=0.05 cutoff, so final statistical
models did not contain any interaction terms. The final model
contained the variables drug use (SP, antifolate, or CQ) and year
of survey as the main predictors, and controlled for potential
confounders including: age, parasite density, hemoglobin level,
sex, and GIS distance to shore.
For all statistical tests, a two sided p,0.05 was considered to be
statistically significant. Data and statistical analyses, including
logistic regression, were performed using SAS software version 9.2
(SAS Institute Inc., Cary, NC, USA).
Results
Of the 503 randomly selected parasite positive samples, 492
(97.8%) samples were successfully genotyped for all drug resistance
SNPs, 250 (96.5%) for baseline and 242 (99.2%) for year 5 survey
samples. Where genotyping failed for any of the markers, data was
reported as missing.
Characteristics of Study Participants
Participants at the year 5 survey were significantly older, lived
farther from the lake shore and the nearest clinic, and had a higher
ITNs and Drug Resistance to SP and CQ
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hemoglobin level, and lower geometric mean parasite density
compared to those at baseline. Significantly more SP but less CQ
use was reported by participants in the year 5 survey than in
baseline. Other characteristics including sex, report of fever,
presence of gametocytes, elevation of compound, use of CTX, and
use of any antimalarial did not differ significantly between year 5
and baseline survey samples (table 1).
Prevalence of SNP Mutations and SP and CQ Genotypes
The prevalence of mutations and proportion of mixed infections
by SNP at baseline and the year 5 survey are summarized in
figure 1. The prevalence of SNP mutations in dhfr and CQ-linked
genes were high initially and remained unchanged at the year 5
survey, with non-significant increases from 90.4% to 94.6% for
dhfr-51, 74.8% to 81.8% for dhfr-59, 97.6% to 100% for dhfr-108,
81.6% to 81.8% for pfcrt-76, and a non-significant decrease from
75.1% to 73.4% for pfmdr1-86. In contrast, a statistically significant
increase (p,0.001) in the prevalence of mutations in both dhps
codons was observed from baseline at 53.2% and 35.6% to the
year 5 survey at 92.3% and 82.6% for dhps-437 and dhps-540,
respectively (figure 1a). Of the total mutations (pure and mixed),
the proportion of mixed infections detected at dhfr-51 (p = 0.0039),
dhfr-59 (p= 0.036), dhps-437 (p,0.0001), and dhps-540 (p,0.0001)
was significantly lower at the year 5 survey compared to baseline
(figure 1b). There was no significant change in the proportion of
mixed infections measured by pfcrt-76 and pfmdr1-86 SNPs and all
samples were pure mutant type for dhfr-108 except for one mixed
sample at the year 5 survey. No mutations in dhfr-164 were found
at either survey.
The overall prevalence of mutations in dhfr (p = 0.0075), dhps
(p,0.0001), and dhfr/dhps combined (p,0.0001) genotypes was
significantly different at baseline compared to the year 5 survey
(figure 2). The dhfr triple mutant prevalence increased from 66.7%
to 76.5%, while the dhps double mutant changed more
dramatically, from 29.6% to 78.5%, from baseline to the year 5
survey (figure 2a, 2b). Quintuple mutations increased from 29.3%
at baseline to 62.0% at the year 5 survey corresponding to a
decrease in double and triple mutations (figure 2c).
Haplotypes of Combined CQ and SP SNP Mutations
In order to evaluate the linkage between multiple mutations of 4
different genes, crt, mdr1, dhfr and dhps [28,29], haplotypes of
combined CQ and SP markers were constructed using single
infection for all seven SNPs (table 2). The wild type haplotype,
K76N86N51C59S108-A437K540, was not detected at either survey.
Thirty-two distinct CQ-SP combined haplotypes were present at
baseline, while only 23 were present at the year 5 survey. The
distinct combined haplotypes detected at the pre- and post-
intervention periods, respectively, comprised of 2 or 0 haplotypes
in single mutants, 2 or 1 haplotypes in double mutants, 5 or 1
haplotypes in triple mutants, 5 shared and 2 different haplotypes in
quadruple mutants, 10 or 8 haplotypes in quintuple mutants, 5
haplotypes in sextuple mutants, and 1 haplotype in septuple
mutant isolates. Most importantly, both the sextuple haploty-
pe,T76N86I51R59N108-G437E540 (containing pfmdr1-86 wild type),
and septuple mutant haplotype, T76Y86I51R59N108-G437E540,
increased dramatically from 1.08% and 5.4% at baseline to
20.72% and 27.9% at the year 5 survey, respectively (table 2). In
addition, the haplotypes containing pfcrt-76 and dhfr-51, 59 and
108 mutations only, regardless of pfmdr1-86, T76N86I51R59N108-
A437K540 and T76Y86I51R59N108-A437K540, significantly decreased
from 9.68% and 13.98% to 1.8% respectively (table 2).
Table 1. Characteristics of study participants at baseline and year 5 survey.
Category/Characteristics Baseline (n=250) Year 5 Survey (n =242) p-value
Male sex (%) 126/250 (50.4) 121/242 (50.0) 0.93
Age, mean (SD), months 23.8 (15.0) 43.3 (17.6) ,0.0001*
Fevera (%) 23/239 (9.6) 21/241 (8.7) 0.73
Hemoglobin, mean (SD), g/dL 7.9 (2.2) 10.2 (1.7) ,0.0001*
Parasite densityb, geometric mean (95% CI), uL 2670 (2263–3156) 1339 (1048–1731) ,0.0001*
Gametocytes present (%) 43/250 (17.2) 56/242 (23.1) 0.1
Euclidean distance, mean (SD), meters
To shore 7029 (2657) 7582 (2530) 0.018*
To nearest clinic 2255 (1017) 2534 (970) 0.0019*
Elevation of compound 1247 (52) 1251 (46) 0.33
Drug usec (%)
SP 4/246 (1.6) 17/236 (7.2) 0.0027*
Cotrimoxazole 13/247 (5.3) 20/242 (8.3) 0.19
CQ 46/247 (18.6) 25/236 (10.6) 0.013*
CQ or SP 50/250 (20.0) 42/242 (17.4) 0.45
Bednet usaged (%) – 223/242 (92.2) –
NOTE. Data are proportion (%) of P. falciparum smear-positive participants with molecular data, unless otherwise indicated. SD, standard deviation; CI, confidence
interval; SP, sulfadoxine-pyrimethamine; CQ, chloroquine.
aBody temperature greater than or equal to 37.5uC at or 48 hours before survey.
bParasite density was log transformed prior to statistical analysis.
cWithin two weeks prior to survey.
dChild slept under bednet .5 days in the past week, bednet usage in the study area was ,5% prior to trial.
*P,0.05, statistically significant difference between baseline and year 5 survey based on chi-squared or two sample t-test (satterthwaite).
doi:10.1371/journal.pone.0026746.t001
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Association between Number of Mutations in SP and CQ
Genotypes and Drug Use or Year of Survey
The final statistical model for the association analysis was
selected based on biologic plausibility, results from univariable
analysis, and backwards elimination strategy. The final model
contained the variables drug use (SP, antifolate, or CQ) and year
of survey as the main predictors, and controlled for age, parasite
density, hemoglobin level, sex, and GIS distance to shore as
potential confounding factors.
The relationship between drug use and drug resistance
genotypes was studied by examining the effect of antifolate, SP,
and CQ use on mutations in their corresponding molecular
markers. Antifolate use was significantly associated with more
mutations in dhps genotype (adjusted odds ratio [OR], 2.3 [95%
confidence interval {CI}, 1.1–4.7]) and, in the univariable model
only, more mutations in dhfr/dhps combined genotype (unadjusted
OR, 2.2 [95% CI, 1.2–3.8]) (table 3). Among participants
reporting SP use alone, the unadjusted odds for having more dhps
mutations (unadjusted OR, 5.6 [95% CI, 1.6–19.4]) and more
dhfr/dhps combined mutations (unadjusted OR, 3.0 [95% CI, 1.2–
7.3]) were significantly higher than for those who reported no SP
use (table 3). These associations did not remain significant after
adjusting for sex, age, hemoglobin level, parasite density, and GIS
distance to shore as well as year of survey. No significant
associations between CQ use and mutations in pfcrt-76 or pfmdr1-
86 were observed in either univariable or multivariable analysis
(table 4).
The association between the year of survey and SP and CQ
genotypes was also explored. The unadjusted odds of having more
mutations in dhfr, dhps, and dhfr/dhps combined genotypes at the
year 5 survey were 1.6 ([95% CI, 1.1–2.4]), 9.2 ([95% CI, 6.2–
13.7]), and 7.5 ([95% CI, 5.2–10.8]) times the odds of having more
mutations at baseline, respectively (table 3). In multivariable
analysis, the association remained significant for dhps genotype
(adjusted OR, 10.3 [95% CI, 6.3–17.0]) and dhfr/dhps combined
genotype (adjusted OR, 8.7 [95% CI, 5.5–13.9]) (table 3) after
adjusting for antifolate drug use and other potential confounders.
The year of survey was not associated with the pfcrt-76 or pfmdr1-86
mutant in either univariable or multivariable analysis (table 4).
Discussion
With the scale-up of ITNs as a malaria control strategy [7],
assessing the impact of the transmission-reducing intervention on
the spread of drug resistance has become a particularly important
concern. The current understanding of the relationship between
transmission intensity and the spread of drug resistance relies on
the effect of host, parasite, and vector factors [3,12]. In this study,
the effect of sustained transmission reduction by ITNs on the
spread of drug resistance during a shift in national drug policy
from CQ to SP was investigated. The prevalence of gene
mutations associated with drug resistance to SP and CQ between
baseline and five years post-ITN introduction was compared and
explored further to understand how some variables may shape the
dynamics of drug resistance.
Figure 1. Comparison of mutation prevalence by SNP between baseline and year 5 survey. A, Overall prevalence of mutations ((pure
mutations and mixed)/total samples). B, Proportion of mixed infections in total mutations (mixed/(pure mutations and mixed)). Statistical analysis
performed using chi-squared test. * p,0.05, significant difference in prevalence between baseline and year 5 surveys.
doi:10.1371/journal.pone.0026746.g001
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The accumulation of mutations in the dhfr and dhps genes in
response to drug pressure is stepwise and occurs first in the dhfr
gene. In this study, there was a high prevalence of the dhfr triple
mutant parasite (67%) but a relatively lower prevalence of the dhps
double mutant (30%) at baseline. Although SP use in the study
area was limited due to poor availability before the national drug
Figure 2. Prevalence of SP genotypes at baseline and year 5 survey. A, dhfr genotype based on mutations in dhfr-51,59,108. B, dhps
genotype based on mutations in dhps-437,540. C, dhfr/dhps combined genotype based on dhfr and dhps genotypes. Statistical analysis performed
using chi-squared test. The prevalence of dhfr, dhps, and dhfr/dhps combined genotypes were significantly different at baseline compared to the year
5 survey, p,0.05.
doi:10.1371/journal.pone.0026746.g002
Table 2. Haplotypes for CQ and SP resistance markers combined at baseline and year 5 survey.
CQ and SP
Haplotypea,b crt76 mdr186 dhfr 51 dhfr 59 dhfr 108 dhps437 dhps540
Number of
mutations
Baseline
(n =93) N (%)
Year 5 Survey
(n=111) N (%)
Wild Type K aaa N aat N aat C tgt S agc A gct K aaa
Mutant T aca Y tat I att R cgt N aac G ggt E gaa
K N N C S A K 0 0 (0) 0 (0)
K Y N C S A K 1 1 (1.08) 0 (0)
T N N C S A K 1 1 (1.08) 0 (0)
T Y N C S A K 2 2 (2.15) 0 (0)
K N I C N A K 2 3 (3.23) 1 (0.90)
K Y I C N A K 3 4 (4.30) 0 (0)
T N I C N A K 3 8 (8.60) 1 (0.90)
K Y N R N A K 3 1 (1.08) 0 (0)
T N N R N A K 3 1 (1.08) 0 (0)
K N I R N A K 3 1 (1.08) 0 (0)
T Y I C N A K 4 9 (9.68) 3 (2.70)
T Y N R N A K 4 3 (3.23) 1 (0.90)
K Y I R N A K 4 2 (2.15) 1 (0.90)
T N I R N A K 4 9 (9.68) 2 (1.80)
T N I C N G K 4 1 (1.08) 1 (0.90)
T N N R N G K 4 0 (0) 2 (1.80)
K Y I C N G K 4 1 (1.08) 0 (0)
K N I R N G K 4 1 (1.08) 0 (0)
K N I C N G E 4 0 (0) 1 (0.90)
T Y I R N A K 5 13 (13.98) 2 (1.80)
T Y N R N G K 5 1 (1.08) 0 (0)
T Y I C N G K 5 3 (3.23) 2 (1.80)
K Y I R N G K 5 1 (1.08) 1 (0.90)
T N I R N G K 5 2 (2.15) 1 (0.90)
K Y I C N G E 5 1 (1.08) 3 (2.70)
K Y N R N G E 5 1 (1.08) 0 (0)
T N I C N G E 5 3 (3.23) 7 (6.31)
T N N R N G E 5 1 (1.08) 4 (3.60)
K N I R N G E 5 1 (1.08) 3 (2.70)
T Y I R N G K 6 2 (2.15) 4 (3.60)
T Y N R N G E 6 2 (2.15) 5 (4.50)
T Y I C N G E 6 6 (6.45) 11 (9.91)
K Y I R N G E 6 2 (2.15) 1 (0.90)
T N I R N G E 6 1 (1.08) 23 (20.72)
T Y I R N G E 7 5 (5.38) 31 (27.93)
NOTE. CQ, chloroquine; SP, sulfadoxine-pyrimethamine.
aThe construction of the CQ-SP haplotype included pfcrt-76, pfmdr1 -86, dhfr-51,59,108, and dhps-437,540. All samples are single infection for all seven SNPs.
bWild type amino acids are shown in plain font, while mutated amino acids are depicted in bolded font.
doi:10.1371/journal.pone.0026746.t002
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policy change in 1998 [23], the high prevalence of mutations in
dhfr gene at the baseline (1996) could be attributed to both the on-
going use of CTX, which is also an inhibitor of the dhfr and dhps
enzymes [31] and the possible gene flow due to human migration
from the surrounding bay area, where SP use was relatively
common [32] , to this study area. At the year 5 survey, there was a
significant increase in the prevalence of the dhps double mutant
(from 30% to 79%) and dhfr/dhps quintuple mutations (from 20%
to 62%), but a less dramatic increase in dhfr triple mutant (from
67% to 77%) (figure 2). Further analysis showed that SP use alone
and antifolate use (SP and/or CTX) were associated with more
mutations in dhps genotype and dhfr/dhps combined genotype,
although only the association of antifolate use with more mutations
in dhps genotype remained statistically significant after controlling
for multiple confounding factors (table 3). Taken together, it is
clear that increased antifolate drug use, most likely resulting from
drug policy change, played a predominant role in the selection of
SP resistant parasites, leading to the high prevalence of dhps double
and dhfr/dhps quintuple mutations during the period of ITN
intervention. The results from the children in this study are
consistent with the increased prevalence of dhfr and dhps mutations
observed in all age groups in Kisumu, Kenya as well as in
Tanzania after drug policy changed to SP or CTX [33,34,35].
The current study further showed a strong and significant
association between the year 5 survey and more mutations in dhps
and dhfr/dhps combined genotypes (table 3). This association
remained distinct after adjusting for antifolate drug use and other
potential confounders, suggesting that the differences in other
factors between the two survey time points may have regulated the
high prevalence of SP mutations observed at the year 5 survey.
This speculation could rely on the following plausible explanations
of a few proxy factors.
Reduction in transmission intensity presumably lowers the
multiplicity of clonal infections [3]. However, a previous
investigation by our group using neutral microsatellite markers
in a subset of samples used in the present study showed an
unchanged, high overall clonal multiplicity despite the reduction in
EIR five years post-ITN intervention [30]. The counter-intuitive
result from the previous study was surprising and suggested a
strong resilience of the malaria parasite in response to dramatic
transmission reduction after five years of sustained ITN use.
Although the unchanged high level of overall clonal multiplicity
alone has no effect on the spread of drug resistance for the
monogenic-based drug resistant genes, such as SP, the rate of drug
resistance could increase in the presence of intrahost competition
between co-infecting parasite clones (intrahost dynamics) based on
generalized immunity model [36]. In the current study, a
significant decrease in the proportion of mixed infections out of
total mutations for dhfr-51, 59 and dhps-437, 540 SNPs were
observed at the year 5 survey compared to baseline (figure 1B).
This result suggests that intrahost removal of SP drug wild/
sensitive parasite clones is present at the year 5 survey, thus
purifying and expanding drug resistant clones at population level.
However, it is unclear the exact interplay between altered host
immunity due to the transmission reduction by ITN use (not
measured here) and increased antifolate use in the removal of SP
drug sensitive parasites [36].
Table 3. Univariable and multivariable analyses of the association between specific predictors and mutations in dhfr, dhps, and
dhfr/dhps combined.
dhfr Triple Mutanta dhps Mutationsb dhfr/dhps Mutationsc
OR (95% CI) OR (95% CI) OR (95% CI)
Predictor Unadjusted Adjustedd Unadjusted Adjustede Unadjusted Adjustede
Antifolate use
SP and/or CTXf 1.1 (0.6, 2.1) 0.9 (0.5, 1.8) 3.2 (1.6, 6.2)* 2.3 (1.1, 4.7)* 2.2 (1.2, 3.8)* 1.6 (0.9, 2.9)
SP onlyg 1.0 (0.4, 2.7) 0.8 (0.3, 2.1) 5.6 (1.6, 19.4)* 3.4 (0.9, 12.8) 3.0 (1.2, 7.3)* 1.9 (0.7,4.8)
Year of Surveyh 1.6 (1.1, 2.4)* 1.6 (1.0, 2.6) 9.2 (6.2, 13.7)* 10.3 (6.3, 17.0)* 7.5 (5.2, 10.8)* 8.7 (5.5, 13.9)*
NOTE. CI, confidence interval; OR, odds ratio; SP, sulfadoxine-pyrimethamine; CTX, cotrimoxazole.
adhfr triple mutant was analyzed by grouping wild type, single and double genotypes as the reference category.
bdhps mutations were analyzed as 3 genotype categories: (1) wild type, (2) single, and (3) double.
cdhfr and dhps combined mutations were analyzed as 3 genotype categories: (1) wild type, single, double, and triple, (2) quadruple, and (3) quintuple.
dDerived from multivariable logistic regression, controlling for age, sex, parasite density, hemoglobin level, and GIS distance to shore.
eDerived from multivariable cumulative logistic regression, which models the probability of more mutations compared to fewer, controlling for age, sex, parasite
density, hemoglobin level, and GIS distance to shore.
fModel containing SP and/or CTX use as a predictor.
gModel containing SP use only as a predictor.
hYear 5 survey versus baseline.
*Statistically significant, p,0.05.
doi:10.1371/journal.pone.0026746.t003
Table 4. Univariable and multivariable analyses of the
association between specific predictors and mutations in CQ-
linked drug resistance genes.
pfcrt-76 Mutanta pfmdr1-86 Mutanta
OR (95% CI) OR (95% CI)
Predictor Unadjusted Adjustedb Unadjusted Adjustedb
CQ use 1.0 (0.5, 1.9) 1.0 (0.5,1.9) 1.5 (0.8, 2.7) 1.5 (0.8, 2.8)
Year of Surveyc 1.0 (0.6, 1.6) 1.1 (0.6, 2.0) 0.9 (0.6, 1.4) 0.8 (0.5, 1.3)
NOTE. CI, confidence interval; OR, odds ratio; CQ, chloroquine.
apfcrt-76 and pfmdr1-86 mutants were analyzed using wild type as the reference
group.
bDerived from multivariable logistic regression, controlling for age, sex, parasite
density, hemoglobin level, and GIS distance to shore.
cYear 5 survey versus baseline.
*Statistically significant, p,0.05.
doi:10.1371/journal.pone.0026746.t004
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At baseline, the prevalence of pfcrt-76 and pfmdr1-86 mutations
was high at 82% and 75%, respectively, which presumably
resulted from the progression of CQ drug pressure. Despite
decreased CQ drug use due to the change in first line antimalarial
treatment to SP at second year of ITNs trial period and decreased
malaria case treatment due to the transmission reduction by use of
ITNs [23], the high prevalence of CQ gene mutations remained
unchanged between baseline and the year 5 survey (82% and 73%,
respectively). This result could have several explanations. First, the
time frame evaluated in this study may not be sufficient to observe
considerable decreases in mutation prevalence of CQ molecular
markers at such high levels; therefore, long term monitoring is
necessary to detect changes in the prevalence of mutations. A
study conducted in Malawi showed that pfcrt mutant genotype
significantly declined after cessation of CQ use for eight years
[37,38]. Second, CQ was not completely withdrawn from Kenya
after the drug policy shift to SP in 1998 as shown in table 1, hence,
CQ drug pressure presumably was still present. In the year 5
survey that occurred 3 years after the national drug policy change
to SP, 10.6% of participants reported using CQ (table 1),
suggesting that CQ was still available and used in this study area
after the policy shift to SP. Third, the unchanged overall high
clonal multiplicity measured by neutral microsatellite markers as
mentioned before [30] and the absence of intrahost competition
measured by the proportion of mixed infection using CQ markers
in the current study suggest that transmission reduction by the use
of ITNs does not affect the prevalence of CQ mutations. This
explanation corroborates with the theoretical models described
earlier [3,12].
In this study, the haplotypes constructed from CQ and SP
resistance gene SNPs located on different chromosomes were
further analyzed to gain insight into genetic linkage of the multiple
mutations and transmission dynamics of drug resistant parasites.
Many of the haplotypes detected in this study have been reported
previously in Africa [28,29]. Although the most dramatic increase
was noted in the septuple mutant, T76Y86I51R59N108G437E540,
from baseline to the year 5 survey, there was also a substantial
increase in isolates containing the pfmdr1-86 sensitive sextuple
mutant, T76N86I51R59N108G437E540. Additionally, there was a
significant decrease in the haplotypes containing dhfr-51, 59 and
108 mutations and sensitive dhps-437 and 540 (T76N86I51R59-
N108A437K540 and T76Y86I51R59N108A437K540) from baseline to
the year 5 survey. These results revealed a clear selection of dhps
mutations (A437K540 to G437E540) due to increased SP pressure
after policy implementation. The result, strong genetic linkage
between mutations for CQ, particularly pfcrt76, and the accumu-
lation at dhfr and dhps mutations for SP as expected, also suggests
that separate mutations conferring resistance to unrelated drugs
could be coordinated beyond the chromosomal level [28,29]
although molecular pathways involved in the process are still
unknown. The strong linkage between CQ and SP mutations may
also offer a partial explanation to the unchanged high prevalence
of pfcrt-76 mutation (80%) in this study, in which fast accumulation
of dhfr and dhps mutations driven by increased SP pressure may
play a role in preventing the recovery of parasites with wild type
pfcrt (20%). However, this speculation requires further investiga-
tion. Importantly, the higher prevalence of parasites with CQ and
SP combined sextuple and septuple mutant haplotypes that
circulated in this study area in the year 5 survey calls for the
continuation of monitoring both CQ and SP molecular markers in
this area.
There were a few limitations of the current study. First, this
study compared two independent populations from the same study
site at two different points in time; hence the results of drug
resistant molecular markers might be influenced by unmeasured
factors that changed in the study site over the 5 year study period
in addition to the factors investigated. To the best of our
knowledge, other than the ITNs trial and the change in
antimalarial drug policy no other malaria interventions and
associated epidemiological impacts occurred in the study area
during the study period. Despite this, the absence of a nearby
comparison area without community ITN use at the year 5 survey
[18] limited comparisons to quantify the contribution of
transmission reduction by ITN use on the spread of drug
resistance in this study. Second, it is not clear whether drug use
as measured in the current study reflects the proportion of
therapeutic drug use that is mainly influenced by acquired
immunity and/or the level of community drug use that is
regulated by infection risk. Consequently, it was not possible to
completely to dissect the role of drug pressure in these results. It
would be ideal to conduct well-controlled studies in areas with
dramatically different levels of ITN coverage/usage during the
same time period with no drug policy change, since comparing
sites where ITNs have not been distributed to date may not be
feasible and ethical. Such studies would help to assess the net effect
of transmission reduction by ITNs on the spread of antimalarial
drug resistance.
The findings from this study differ with the results from the
studies conducted in Tanzania and Burkina Faso which also
assessed the short or long term effects of ITNs or ITCs on
prevalence of gene mutations linked to SP and CQ, respectively
[9,11]. The discrepancy in the results among the studies could be
due to differences in the study design, level of transmission
reduction, stage of existing drug resistance, change in drug policy
during the study, and other potential confounders. In the
Tanzania study, a reduction in the prevalence of dhfr triple
mutation was observed two years after ITN introduction and
during the two year study period SP was first line drug treatment
for malaria. The study conducted in Burkina Faso, where CQ
remained first line treatment during study period, reported no
change in the prevalence of molecular markers linked to CQ and
SP after seven years of ITC intervention. The present study
showed that increased antifolate drug use likely led to the high
prevalence of SP mutations five years post-ITN intervention and
reduced transmission did not change the existing high prevalence
of CQ mutations. In addition, the difference in the degree of local
gene flow resulting from human movement between intervention
and non-intervention areas could be another factor for the
inconsistent results among the different studies. Although the
previous short-term study concluded that transmission reducing
interventions such as ITNs may help restore the susceptibility of
SP [9], there is no evidence from the current study that sustained
transmission reduction by ITNs reduces the prevalence of drug
resistance genes associated with SP and CQ.
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